http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
안명주,한지연,김동완,조병철,강진형,김상위,James Chih-Hsin Yang,Tetsuya Mitsudomi,이종석 대한암학회 2020 Cancer Research and Treatment Vol.52 No.1
Purpose Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261). Materials and Methods Enrolled patients had EGFR T790M-positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR). Results In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (n=62), ORR was 74% (95% confidence interval [CI], 61.5 to 84.5) and median duration of response was 9.8 months (95% CI, 7.1 to 16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3 to 15.0; data cutoff November 1, 2016), and median overall survival was 29.2 months (95% CI, 24.8 to 35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhea, and decreased appetite (each 32%). Conclusion Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.
안명주 한양대학교 의과대학 1998 한양의대 학술지 Vol.18 No.2
Cancer is one of the major causes of death in the world. Cancer begins when a cell breaks free from the normal restraints on uncontrolled growth and spread. Over the past 25 years, scientists have uncovered a set of basic principles that govern the development of cancer. The cells in a tumor descend from a common ancestral cell that at one point initiated a program of inappropriate reproduction. Furthermore, the malignant transformation of a cell comes about through the accumulation of mutations in specific classes of the genes within it. Among them, two gene classes, oncogenes and tumor suppressor genes, account for much of the uncontrolled cell proliferation seen in human cancers. More than half the cancer death can be attributed to tobacco smoke and diet in worldwide. Therefore, a cancer death can be avoided through prevention strategies, including never smoking and eating certain vegetables and other foods that counteract the activity of cancer-causing agents (carcinogens) in the body. Improvements in medical imaging technology and the power of the new molecular diagnostic tools will be able to diagnose the cancer in early stage. Although the mainstays of cancer treatment - surgery, radiation and chemotherapy- are being refined and combined in ways that can help patients enjoy longer and more fulfilling lives, the new approaches to cancer treatment such as immunotherapy and the molecularly targeted approach (gene therapy to restore normal suppressor gene, antisense inhibitors for oncogene, angiogenesis inhibitors, etc.) would combat cancers without the devastating side effects of many current therapies in the near future.
안명주 ( An Myeong Ju ) 대한소화기학회 2004 대한소화기학회지 Vol.43 No.2
Despite the reduced incidence and mortality, gastric cancer remains the second leading cause of cancer death in Korea. Metastatic gastric cancer is regarded as an incurable condition, and chemotherapy is usually accepted as standard palliation. A number of randomized studies were performed comparing supportive care strategies with intravenous chemotherapy. The results demonstrated that systemic treatment can actually improve overall survival and quality of life to a certain extent. However, there is no agreement for standard of treatment in this setting. Recently, a number of newer compounds such as taxanes, topoisomerase I inhibitors and oral fluoropyrimidines have been intensively studied. The surgical resection still remains as the cornerstone of gastric cancer treatment. However, the high rate of recurrence and poor survival after surgery provides a rationale for the early use of adjuvant treatment. A large intergroup study (INT-0116) showed that combined chemoradiation following to gastric resection improves median time to relapse and overall survival. Future advances in the therapy of advanced and resectable gastric cancers may come from the application of new cytotoxic and molecularly targeted agents such as growth factor receptor antagonists and anti-angiogenesis agents. (Korean J Gastroenterol 2004;43: 75-81)